two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]). Two different doses were tested, and dose-limiting toxicity was neutropenia. A target dose of 200 mg BID was identified and chosen ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...